Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Pitfalls in the diagnosis of myositis.

Chinoy H, Lilleker JB.

Best Pract Res Clin Rheumatol. 2020 Feb 13:101486. doi: 10.1016/j.berh.2020.101486. [Epub ahead of print] Review.

PMID:
32063440
2.

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis.

Betteridge Z, Chinoy H, Vencovsky J, Winer J, Putchakayala K, Ho P, Lundberg I, Danko K, Cooper R, McHugh N.

Rheumatology (Oxford). 2019 Sep 17. pii: kez406. doi: 10.1093/rheumatology/kez406. [Epub ahead of print]

PMID:
31728542
3.

The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients.

Tansley SL, Betteridge Z, Lu H, Davies E, Rothwell S, New PP, Chinoy H, Gordon P, Gunawardena H, Lloyd M, Stratton R, Cooper R, McHugh NJ.

Rheumatology (Oxford). 2019 Oct 26. pii: kez504. doi: 10.1093/rheumatology/kez504. [Epub ahead of print]

PMID:
31665469
4.

A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies.

Oldroyd A, Little MA, Dixon W, Chinoy H.

BMC Rheumatol. 2019 Oct 21;3:41. doi: 10.1186/s41927-019-0088-1. eCollection 2019.

5.

Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study.

Parker MJS, Oldroyd A, Roberts ME, Ollier WE, New RP, Cooper RG, Chinoy H.

Rheumatol Adv Pract. 2018 Sep 17;2(2):rky035. doi: 10.1093/rap/rky035. eCollection 2018.

6.

Genetics of idiopathic inflammatory myopathies: insights into disease pathogenesis.

Rothwell S, Chinoy H, Lamb JA.

Curr Opin Rheumatol. 2019 Nov;31(6):611-616. doi: 10.1097/BOR.0000000000000652.

7.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group.

Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5.

PMID:
31397289
8.

Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria.

To F, Parker MJS, Ventín-Rodríguez C, Lilleker JB, Chinoy H.

Rheumatology (Oxford). 2019 Dec 1;58(12):2331-2333. doi: 10.1093/rheumatology/kez253. No abstract available.

9.

Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply.

Oldroyd A, Sergeant JC, New RP, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H.

Rheumatology (Oxford). 2019 Nov 1;58(11):2073-2074. doi: 10.1093/rheumatology/kez329. No abstract available.

10.

Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS.

Jani M, Chinoy H, Barton A; for OUTPASS.

J Rheumatol. 2019 Aug 1. pii: jrheum.190253. doi: 10.3899/jrheum.190253. [Epub ahead of print]

PMID:
31371650
11.

Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing.

Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, Carr DF, Molokhia M, Liu X, Bis JC, Ahmed A, Liu X, Hallberg P, Yue QY, Magnusson PKE, Brisson D, Wiggins KL, Morrison AC, Khoury E, McKeigue P, Stricker BH, Lapeyre-Mestre M, Heckbert SR, Gallagher AM, Chinoy H, Gibbs RA, Bondon-Guitton E, Tracy R, Boerwinkle E, Gaudet D, Conforti A, van Staa T, Sitlani CM, Rice KM, Maitland-van der Zee AH, Wadelius M, Morris AP, Pirmohamed M, Palmer CAN, Psaty BM, Alfirevic A; PREDICTION-ADR Consortium and EUDRAGENE.

PLoS One. 2019 Jun 26;14(6):e0218115. doi: 10.1371/journal.pone.0218115. eCollection 2019.

12.

Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink.

Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd JS, Psaty BM, Molokhia M, Lapeyre-Mestre M, Conforti A, Alfirevic A, van Staa T, Pirmohamed M.

Clin Pharmacol Ther. 2019 Dec;106(6):1353-1361. doi: 10.1002/cpt.1557. Epub 2019 Jul 31.

13.

Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy: An Unusual Presentation.

Wig S, Rashid A, Filer C, Chinoy H.

J Clin Rheumatol. 2019 Jun 18. doi: 10.1097/RHU.0000000000001094. [Epub ahead of print] No abstract available.

PMID:
31220053
14.

Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles.

Reynolds JA, Briggs TA, Rice GI, Darmalinggam S, Bondet V, Bruce E, Khan M, Haque S, Chinoy H, Herrick AL, McCarthy EM, Zeef L, Hayes A, Duffy D, Parker B, Bruce IN.

Arthritis Res Ther. 2019 Jun 14;21(1):147. doi: 10.1186/s13075-019-1929-4.

15.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

16.

Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies.

Mahler M, Betteridge Z, Bentow C, Richards M, Seaman A, Chinoy H, McHugh N.

Front Immunol. 2019 Apr 30;10:848. doi: 10.3389/fimmu.2019.00848. eCollection 2019.

17.

Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.

Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N; UKMyonet contributors.

J Autoimmun. 2019 Jul;101:48-55. doi: 10.1016/j.jaut.2019.04.001. Epub 2019 Apr 13.

18.

The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.

Rutkowski D, Chinoy H, Warren RB.

Dermatol Ther (Heidelb). 2019 Jun;9(2):373-381. doi: 10.1007/s13555-019-0290-5. Epub 2019 Mar 16.

19.

Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.

Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY.

Autoimmun Rev. 2019 May;18(5):535-541. doi: 10.1016/j.autrev.2019.03.010. Epub 2019 Mar 4.

PMID:
30844552
20.

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis.

Lilleker JB, Hodgson R, Roberts M, Herholz K, Howard J, Hinz R, Chinoy H.

Ann Rheum Dis. 2019 May;78(5):657-662. doi: 10.1136/annrheumdis-2018-214644. Epub 2019 Feb 13.

21.

Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.

Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK, Misbah SA, Oni L, Price-Kuehne FE, Salama AD, Workman S, Wrench D, Karim MY.

Rheumatology (Oxford). 2019 May 1;58(5):889-896. doi: 10.1093/rheumatology/key394.

PMID:
30590695
22.

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.

Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H; UKMyoNet.

Rheumatology (Oxford). 2019 Apr 1;58(4):650-655. doi: 10.1093/rheumatology/key357.

23.

The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort.

Parker MJS, Oldroyd A, Roberts ME, Lilleker JB, Betteridge ZE, McHugh NJ, Herrick AL, Cooper RG, Chinoy H.

Rheumatology (Oxford). 2019 Mar 1;58(3):468-475. doi: 10.1093/rheumatology/key343.

24.

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies.

Oldroyd A, Chinoy H.

Curr Opin Rheumatol. 2018 Nov;30(6):606-613. doi: 10.1097/BOR.0000000000000549. Review.

25.

Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis.

Parkes JE, Rothwell S, Oldroyd A, Chinoy H, Lamb JA; Myositis Genetics Consortium (MYOGEN).

Arthritis Res Ther. 2018 Jun 8;20(1):117. doi: 10.1186/s13075-018-1617-9.

26.

Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis.

Coates LC, Savage LJ, Chinoy H, Laws PM, Lovell CR, Korendowych E, Mahmood F, Mathieson HR, McGonagle D, Warren RB, Waxman R, Helliwell PS.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1530-1534. doi: 10.1111/jdv.14971. Epub 2018 May 9.

27.

Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies.

Lilleker JB, Diederichsen ACP, Jacobsen S, Guy M, Roberts ME, Sergeant JC, Cooper RG, Diederichsen LP, Chinoy H.

Rheumatology (Oxford). 2018 Jun 1;57(6):1041-1046. doi: 10.1093/rheumatology/key031.

28.

Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms.

Lilleker JB, Bukhari M, Chinoy H.

Rheumatology (Oxford). 2019 Mar 1;58(3):375-376. doi: 10.1093/rheumatology/key043. No abstract available.

PMID:
29529264
29.

Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab.

Parker MJ, Roberts ME, Lorigan PC, du Plessis DG, Chinoy H.

BMJ Case Rep. 2018 Feb 8;2018. pii: bcr-2017-223249. doi: 10.1136/bcr-2017-223249.

30.

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.

Ann Rheum Dis. 2018 Apr;77(4):602-611. doi: 10.1136/annrheumdis-2017-212149. Epub 2018 Jan 13.

PMID:
29331962
31.

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far.

Jani M, Dixon WG, Chinoy H.

Rheumatology (Oxford). 2018 Nov 1;57(11):1896-1907. doi: 10.1093/rheumatology/kex434. Review.

32.

Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al.

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Jordan P, Benveniste O, Danieli MG, Dankó K, Phuong Thuy NT, Vázquez-Del Mercado M, Andersson H, Paepe B, De Bleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge Z, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors.

Ann Rheum Dis. 2018 Aug;77(8):e51. doi: 10.1136/annrheumdis-2017-212382. Epub 2017 Dec 19. No abstract available.

PMID:
29259048
33.

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) .

RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.

34.

Patient-centred standards of care for adults with myositis.

Lilleker JB, Gordon P, Lamb JA, Lempp H, Cooper RG, Roberts ME, Jordan P, Chinoy H; UK Myositis Network (UKMYONET); Myositis UK.

BMC Rheumatol. 2017 Nov 28;1:4. doi: 10.1186/s41927-017-0002-7. eCollection 2017.

35.

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland).

Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.

36.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).

Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Erratum in: Ann Rheum Dis. 2018 Sep;77(9):e64.

37.

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.

Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, García-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J, Aggarwal R; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Rheumatology (Oxford). 2017 Nov 1;56(11):1884-1893. doi: 10.1093/rheumatology/kex226.

38.

Co-presentation of adult-onset systemic lupus erythematosus and nemaline myopathy.

Hindocha A, Klimiuk P, Roberts M, Pal P, Evangelista T, Lochmüller H, Chinoy H.

Rheumatology (Oxford). 2017 Nov 1;56(11):2034-2035. doi: 10.1093/rheumatology/kex252. No abstract available.

PMID:
28977494
39.

The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, Thuy NTP, Vazquez-Del Mercado M, Andersson H, De Paepe B, deBleecker JL, Maurer B, McCann LJ, Pipitone N, McHugh N, Betteridge ZE, New P, Cooper RG, Ollier WE, Lamb JA, Krogh NS, Lundberg IE, Chinoy H; all EuroMyositis contributors.

Ann Rheum Dis. 2018 Jan;77(1):30-39. doi: 10.1136/annrheumdis-2017-211868. Epub 2017 Aug 30.

40.

Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis.

Howells L, Chisholm A, Cotterill S, Chinoy H, Warren RB, Bundy C.

Arthritis Care Res (Hoboken). 2018 Feb;70(2):295-302. doi: 10.1002/acr.23330. Epub 2017 Dec 29.

41.

Rheumatology training in Poland vs. United Kingdom.

Lazarewicz K, Chinoy H.

Reumatologia. 2017;55(3):120-124. doi: 10.5114/reum.2017.68910. Epub 2017 Jul 18. Review.

42.

Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment.

Oldroyd A, Lilleker J, Chinoy H.

Clin Med (Lond). 2017 Jul;17(4):322-328. doi: 10.7861/clinmedicine.17-4-322. Review.

43.

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Ann Rheum Dis. 2017 May;76(5):792-801. doi: 10.1136/annrheumdis-2017-211400.

44.

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.

Arthritis Rheumatol. 2017 May;69(5):898-910. doi: 10.1002/art.40064. Epub 2017 Apr 6.

45.

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K; BSRBR-RA*; BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL.

RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. Erratum in: RMD Open. 2017 Feb 23;3(1):e000314corr1.

46.

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Lilleker JB, Rietveld A, Pye SR, Mariampillai K, Benveniste O, Peeters MT, Miller JA, Hanna MG, Machado PM, Parton MJ, Gheorghe KR, Badrising UA, Lundberg IE, Sacconi S, Herbert MK, McHugh NJ, Lecky BR, Brierley C, Hilton-Jones D, Lamb JA, Roberts ME, Cooper RG, Saris CG, Pruijn GJ, Chinoy H, van Engelen BG; all UKMYONET contributors.

Ann Rheum Dis. 2017 May;76(5):862-868. doi: 10.1136/annrheumdis-2016-210282. Epub 2017 Jan 25.

47.

Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum.

Rothwell S, Cooper RG, Lundberg IE, Gregersen PK, Hanna MG, Machado PM, Herbert MK, Pruijn GJM, Lilleker JB, Roberts M, Bowes J, Seldin MF, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Platt H, Molberg Ø, Benveniste O, Radstake TRDJ, Doria A, De Bleecker J, De Paepe B, Gieger C, Meitinger T, Winkelmann J, Amos CI, Ollier WE, Padyukov L, Lee AT, Lamb JA, Chinoy H; Myositis Genetics Consortium.

Arthritis Rheumatol. 2017 May;69(5):1090-1099. doi: 10.1002/art.40045. Epub 2017 Apr 4.

48.

Erratum Corrige.

Tansley S, Shaddick G, Christopher-Stine L, Sharp C, Dourmishev L, Maurer B, Chinoy H, McHugh N.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1127. Epub 2016 Nov 29. No abstract available.

49.

A Literature Review of Eosinophilic Fasciitis with an Illustrative Case.

Das J, Chinoy H, Dick J, Matthews R, Roberts M.

Curr Rheumatol Rev. 2017;13(2):113-120. doi: 10.2174/1573397112666161007154703. Review.

PMID:
27839505
50.

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.

Jani M, Gavan S, Chinoy H, Dixon WG, Harrison B, Moran A, Barton A, Payne K.

Rheumatology (Oxford). 2016 Dec;55(12):2131-2137. Epub 2016 Aug 29.

Supplemental Content

Loading ...
Support Center